INmune Bio Inc. INMB
At closeNov 6, 2026, 7:58 PM EST
After hours · Nov 6, 7:58 PM ET
- YTD
- -27.56%
- 1 year
- -30.67%
- Market cap
- 34.98M
- Revenue (ttm)
- 42.00K
- EPS (ttm)
- -0.67
- Shares out
- 22.17M
- Forward P/E
- -2.23
- YTD return
- -27.56%
- 1-year return
- -30.67%
- Volume
- 677.06K
- Avg volume
- 327.81K
- Open
- 1.18
- Previous close
- 1.18
- Day's range
- 1.06 – 1.26
- 52-week range
- 1.12 – 2.51
- Beta
- 1.85
- Price target
- 19.83 (+1655.2%)
- Earnings date
- Aug 1, 2024
3M -0.96 (-45.93%)
Key statistics
- Enterprise value
- 66.92M
- PEG ratio
- 0.00
- Price / sales
- 2402.02
- Price / book
- 2.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.76M
- Total cash
- 33.55M
- Total debt
- 2.91M
- Return on equity
- -98.96%
- Short % of float
- 20.96%
- 50-day average
- 5.27
- 200-day average
- 7.78
Analyst view
- Target (low)
- 16.00
- Target (mean)
- 19.83
- Target (high)
- 22.00
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate -0.556.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.49 | -0.60 | -0.11 | -22.45% |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | -0.50 | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.61 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.47 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Baird | init | — | Outperform |
| May 24, 2022 | BTIG | main | — | Buy |
| May 24, 2022 | B. Riley Securities | down | Buy | Neutral |
| Jan 24, 2022 | B. Riley Securities | main | — | Buy |
| Apr 21, 2021 | B. Riley Securities | init | — | Buy |
| Nov 9, 2020 | HC Wainwright & Co. | main | — | Buy |
About INmune Bio Inc.
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inmunebio.com
News
INmune Bio Q3 2026 Earnings Call Transcript 
INmune Bio Q3 EPS $(0.17) Misses $(0.15) Estimate - INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA
INmune Bio And Quantum Computing Inc. Partner To Use Quantum AI To Identify New Treatment Applications For Alzheimer’s Drug XPro 
Full Transcript: INmune Bio Q2 2026 Earnings Call 
INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe 
Earnings Scheduled For March 30, 2026 
Earnings Scheduled For October 30, 2025 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Earnings Scheduled For August 7, 2025
Your note
Sign in to keep a note on INMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JUDA SCOTT | Director | Purchase | Jun 24, 2024 | 0 |
| LOWDELL MARK WILLIAM | Officer and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 18, 2024 | 1,510,810 |
| MOSS DAVID J. | Chief Financial Officer | Purchase | Sep 29, 2024 | 1,285,870 |
| SCHROEDER TIMOTHY J | Director | Sale | Jul 11, 2023 | 0 |
| TESI RAYMOND JOSEPH | Chief Executive Officer | Purchase | Sep 11, 2024 | 1,554,110 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.24% | 939,468 | 4.27M | Sep 29, 2024 |
| Praetorian Pr LLC | 3.52% | 780,800 | 3.55M | Sep 29, 2024 |
| Vanguard Group Inc | 3.25% | 720,712 | 3.28M | Sep 29, 2024 |
| CVI Holdings, LLC | 2.69% | 596,372 | 2.71M | Jun 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 1.67% | 369,438 | 1.68M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.55% | 344,466 | 1.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.96% | 434,271 | 1.98M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.40% | 310,909 | 1.41M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 165,874 | 754.73K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 131,179 | 596.86K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 125,003 | 568.76K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 76,154 | 346.50K | Oct 30, 2024 |